One-year data on immunogenicity and breakthrough infections in patients with solid tumors vaccinated against COVID-19 during systemic cancer treatment

A A M van der Veldt*, S F Oosting, R S N Fehrmann, C H GeurtsvanKessel, R S van Binnendijk, A-M C Dingemans, E F Smit, T J N Hiltermann, G den Hartog, M Jalving, T T Westphal, A Bhattacharya, F de Wilt, S M Ernst, A Boerma, L van Zijl, G F Rimmelzwaan, P Kvistborg, C A C M van Els, N Y RotsD van Baarle, J B A G Haanen, E G E de Vries

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)
Original languageEnglish
Article number100785
JournalESMO Open
Volume8
Issue number1
DOIs
Publication statusPublished - Feb 2023

Bibliographical note

Funding Information:
The study is funded by ZonMw , the Netherlands Organisation for Health Research and Development .

Funding Information:
AAMvdV reports consultancy fees from BMS, Merck Sharp & Dohme (MSD), Merck, Sanofi, Eisai, Pfizer, Ipsen, Roche, Pierre Fabre, and Novartis; and travel support from Bayer, Roche, Novartis, and Pfizer (all paid to the institution). SFO reports research grants from Novartis and Celldex Therapeutics; and consultancy fees from Genmab, Merck, and Bristol Myers Squibb (BMS; all paid to the institution). AMCD reports consultancy fees from Roche, Boehringer Ingelheim, Amgen, Bayer, PharmaMar, Sanofi, and Daiichi (all paid to the institution); speaker fees from Eli Lilly, AstraZeneca, Jansen, Chiesi, and Takeda (all paid to the institution); and research support from BMS, AbbVie, and Amgen (all paid to the institution). EFS reports consultancy fees from Eli Lilly (all paid to the institution); speaker fees from AstraZeneca, Boehringer Ingelheim, and Daiichi Sankyo (all paid to the institution); and advisory board fees from AstraZeneca, Bayer, BMS, MSD, Merck, Novartis, Pfizer, Roche Genentech, Roche Diagnostics, and Takeda (all paid to the institution). TJNH reports advisory board fees from BMS, AstraZeneca, Merck, Pfizer, Roche, and MSD (all paid to the institution). MJ reports consultancy fees from AstraZeneca and Pierre Fabre (all paid to the institution). GFR reports funding from the Alexander von Humboldt Foundation (paid to the institution). JBAGH reports consultancy fees from Achilles Therapeutics, BioNTech, BMS, Immunocore, Instil Bio, Molecular Partners, MSD, Gadeta, Merck Serono, Neogene Therapeutics, Novartis, Pfizer, PokeAcel, Roche/Genentech, Sanofi, and T-Knife (paid to the institution); consultancy fees from Neogene Tx; speaker fees from Ipsen, Eisai, and Novartis (paid to the institution); research grants from Asher-Bio, BMS, BioNTech, MSD, and Novartis (paid to the institution); and stock in Neogene Tx. EGEdV reports an advisory role at Daiichi Sankyo, NSABP, and Sanofi; and research funding from Amgen, AstraZeneca, Bayer, Chugai Pharma, Crescendo, CytomX Therapeutics, G1 Therapeutics, Genentech, Nordic Nanovector, Radius Health, Regeneron, Roche, Servier, and Synthon (all paid to the institution). All other authors have declared no conflicts of interest.

Cite this